Menu
Washingtoner
  • Home
  • Technology
  • Boeing
  • Daryl Guberman
  • Aerospace
  • Health
  • Business
  • ANSI-ANAB
  • Services
Washingtoner

Global Addiction Treatment Market to Surpass US$ 12,210.0 Million by 2028, Says Coherent Market Insights
Washingtoner/10152734

Trending...
  • Tacoma: Lincoln Avenue Bridge to Close Saturday, April 18 for Asphalt Repairs
  • Su Che Publishing Announces New Children's Book Celebrating Vaisakhi Festival
  • Permian Museum Adds Photos of Fossils Discovered on a Meteorite
SEATTLE, Jan. 28, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global addiction treatment market is estimated to be valued at US$ 8,297.0 million in 2021 and is expected to exhibit a CAGR of 5.3% over the forecast period (2021-2028).

Key Trends and Analysis of the Global Addiction Treatment Market:


Key trends in the market include the rising prevalence of addicted population, increasing product approvals and launches, initiatives by various organizations towards de-addiction, and increasing collaborations, partnerships, mergers and acquisitions among key players. These key trends are expected to aid in the growth of the addiction treatment market.

For instance, in May 2018, US WorldMeds LLC a Kentucky-based specialty pharmaceutical company received the U.S. Food and Drug Administration approval for its novel drug lofexidine hydrochloride (Lucemyra) for mitigation of opioid withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.

Moreover, various government and private organizations are taking initiatives to spread awareness about nicotine de-addiction, which supports addicted person to quit smoking with the help of smoking cessation products. For instance, in 2017, the Public Health England launched US$ 1.3 million smoking cessation campaign to increase awareness to quit smoking.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4853

Furthermore, key players operating in the global addiction treatment market are focusing on adoption of inorganic growth strategies such as acquisitions, mergers, partnerships, and collaborations, in order to strengthen their market presence in the global market. For instance, in August 2018, Elite Laboratories Inc. a specialty pharmaceutical company partnered with Glenmark Pharmaceuticals Ltd. a leading integrated research-based, global pharmaceutical company for distribution of its recently U.S. FDA approved methadone hydrochloride 5 mg and 10 mg tablets. As per the partnership Glenmark Pharmaceuticals, Inc., will sell and distribute methadone in the U.S. for Elite and Elite will receive manufacturing license for methadone.

More on Washingtoner
  • EduCare Inc. Bridges Critical Gap in Breast Cancer Education with Spanish COPE Library Launch
  • Engineering leaders from industry, academia to gather at IISE Annual Conference & Expo in Arlington, Texas
  • AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • BestDoc Launches AI Call Center for Healthcare
  • Acuvance Appoints Sandeep Sabharwal to Board of Directors, Strengthening Leadership to Support Continued Platform Growth

Additionally, in March 2018, GlaxoSmithKline plc.(GSK) entered into an agreement to buyout Novartis AG a Switzerland based global healthcare company stake in the Consumer Healthcare joint venture. According to this agreement, Novartis AG divested its 36.5% stake in a consumer healthcare Joint Venture for total deal value of US$ 13 billion. This joint venture allows GSK to add Novartis' Nicotinell nicotine patch product into its portfolio. This product relieves and prevent cravings and withdrawl symptoms of nicotine. These factors are expected to boost growth of the addiction treatment market over the forecast period.

Key Market Takeaways:

The global addiction treatment market is expected to exhibit a CAGR of 5.3% over the forecast period, owing to increase in number of product approvals. For instance, in 2017, Akorn, Inc. and American generic pharmaceuticals manufacturer received the U.S. Food and Drug Administration (FDA) approval for generic versions of Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) multi-dose vial. It is use treatment of opioid dependence. This generic drug is approved for temporary treatment of patients with opioid dependence, who are unable to take oral medication.

Among drug type, nicotine replacement therapies segment accounted for the largest market share in forecast period, owing to rising product launches. In 2018, Epic Pharma, LLC a generic pharmaceutical company launched Methadone Hydrochloride Tablets, USP in 5mg and 10mg strengths, the generic equivalent of Dolophine. Methadone Hydrochloride Tablets, USP are indicated for the treatment of opioid addiction as well as for management of pain indication.

Key players operating in the global addiction treatment market include Alkremes Plc., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Titan Pharmaceuticals, Inc., Pfizer, Inc., GlaxoSmithKline plc. Johnson & Johnson, Perrigo Company plc., Cipla Limited, Hikma Pharmaceuticals Plc., Dr. Reddy's Laboratories Limited, Indivior Inc., and Mylan N.V.

Request for Customization @
https://www.coherentmarketinsights.com/insight/request-customization/4853

More on Washingtoner
  • Grange Insurance Association to Rebrand as Granwest Insurance on July 1, 2026
  • Dr. Rosendo Icochea, MD Recognized for Contributions to Surgical Education and Medical Research
  • Giftella Launches AI Gift-Finder App That Replaces Guesswork With Personalized Picks in Seconds
  • Beverly.io Announces Nationwide Expansion and Poppins Payroll Partnership for Families
  • City Council Adopts Resolution Transmitting 'Connect Tacoma' Ballot Measure to Pierce County Auditor for August 4, 2026 Primary Election Ballot

Detailed Market Segmentation:

Global Addiction Treatment Market, By Drug Type:
  • Opioid Addiction
    • Methadone
    • Buprenorphine
    • Naltrexone
  • Alcohol Addiction
    • Acamprosate
    • Disulfiram
    • Naltrexone
    • Others
  • Nicotine Replacement Therapies
    • Nicotine Gums
    • Nicotine Patches
    • Nicotine Lozenges
    • Nicotine Spray
    • Nicotine Inhaler
    • Nicotine Sublingual Tablets
  • Non-Nicotine Medication
    • Varenicline
    • Bupropion (Zyban)

Global Addiction Treatment Market, By Region:
  • North America
    • By Country:
      • U.S.
      • Canada
  • Europe
    • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Latin America
    • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East & Africa
    • By Country:
      • GCC Countries
      • Israel
      • South Africa
      • Rest of Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/4853

About Us:

Coherent Market Insights
is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US
: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

SOURCE Coherent Market Insights
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Dividend Stock Guru Unveils High Yield Dividend Stock Research Reports
  • Charging Into the $30 Billion Heart Failure Market with Late-Stage Momentum, Breakthrough Data, & Strong Financial Backing: Cardiol Therapeutics $CRDL
  • All American Home Renovators: Transforming Bathrooms into Masterpieces, One Home at a Time
  • Bold Beauty Project Celebrates Anniversary with Collaborative Exhibition at FIU's Miami Beach Urban Studios
  • Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation
  • Vangal Invests $8.5M in Peridot, Expanding into Enterprise AI Governance and Shadow AI Control
  • Bold Beauty Project Announces Exhibition at Palazzo Mora Venice, Italy
  • Financial Educator Jessica Perrone Launches Free "3 Stages of Building Wealth" Course for Women
  • Captain Notepad Expands Free Custom Design Services Across Full Product Line
  • Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
  • YOKE Expands NIL Club Into Athlete-Led Commerce With Athlete Merch Launch
  • Floor Kings Announces Official Launch of Premier Epoxy Flooring Services Across Arizona
  • UK Buyers Purchase Luxury Home in Keene's Pointe, Windermere (Orlando, Florida)
  • Instant IP Launches Rapid Takedown Service to Combat IP Theft, Deepfakes, and Copycat Websites
  • Tacoma: Lincoln Avenue Bridge to Close Saturday, April 18 for Asphalt Repairs
  • City of Tacoma Invites Community to Shape the Future of Their Neighborhoods at Upcoming Code Update Event
  • Su Che Publishing Announces New Children's Book Celebrating Vaisakhi Festival
  • Permian Museum Adds Photos of Fossils Discovered on a Meteorite
  • This Saturday: Open House for Manalapan's Newest Single Family Home Community
  • Radarsign™ Awarded Sourcewell Contract Expanding Access to Traffic Safety Solutions
_catLbl0 _catLbl1

Popular on Washingtoner

  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals - 543
  • A Letter From the Tacoma City Council to the Sound Transit Board
  • Foiling Freaks Launches New Online Platform Dedicated to Foiling Board Sports
  • Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
  • Spokane: US 195 Project To Improve Traffic Safety
  • JEGS Launches Modern, Secure Payments Powered by PhaseZero.ai
  • Spokane: 2025 Longitudinal Systems Analysis Shows Decreased Need for Homeless Services, Increase in Successful Exits to Stability
  • Tacoma: Lincoln Avenue Bridge to Close Saturday, April 18 for Asphalt Repairs
  • Heritage at Manalapan Introduces New Single-Family Home Community in One of Monmouth County's Most Desirable Locations
  • Mensa Brings National Board Game Competition to Northern Virginia April 16-19

Similar on Washingtoner

  • Revenue Optics Completes Full Commercial Buildout. A Nine-Month-Old Firm Built on 25 Years of Distribution Expertise. Five Clients From $200M to $3B
  • AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • BestDoc Launches AI Call Center for Healthcare
  • Acuvance Appoints Sandeep Sabharwal to Board of Directors, Strengthening Leadership to Support Continued Platform Growth
  • $7.6 Billion US Crypto ATM Market by 2034; California and Texas Crypto ATM Deployments for Bitcoin Bancorp (Stock Symbol: BCBC); 1000 Kiosk Inventory
  • iVAM2-ST2110 to Simplify IP Transitions and Reduce Monitoring Complexity
  • Advantage Marketing Launches 3-Minute Assessment to Help SMBs Diagnose and Fix Marketing Gaps
  • Contracting Resources Group Named to the 2026 Inc. Regionals: Mid-Atlantic List
  • Dividend Stock Guru Unveils High Yield Dividend Stock Research Reports
  • Charging Into the $30 Billion Heart Failure Market with Late-Stage Momentum, Breakthrough Data, & Strong Financial Backing: Cardiol Therapeutics $CRDL
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute